eptaloprost: prodrug for cicaprost; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6436047 |
| CHEMBL ID | 2105604 |
| SCHEMBL ID | 571696 |
| MeSH ID | M0184826 |
| Synonym |
|---|
| eptaloprost |
| 4-[(2e)-2-[(3as,4s,5r,6as)-5-hydroxy-4-[(3s,4s)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]ethoxy]butanoic acid |
| 4-(2-((2e,3as,4s,5r,6as)-hexahydro-5-hydroxy-4-((3s,4s)-3-hydroxy-4-methyl-1,6-nonadiyny)-2(1h)-pentalenylidene)ethoxy)butyric acid |
| unii-93x6a56w84 |
| eptaloprostum |
| 93x6a56w84 , |
| 90693-76-8 |
| eptaloprost [inn] |
| eptaloprostum [latin] |
| CHEMBL2105604 |
| eptaprost |
| SCHEMBL571696 |
| DTXSID70869060 |
| Q27271619 |
Eptaloprost is a novel concept PGI2-mimetic, which is designed to be activated to the pharmacologically potent cicaprost via beta-oxidation.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eptaloprost is a novel concept PGI2-mimetic, which is designed to be activated to the pharmacologically potent cicaprost via beta-oxidation. " | ( Bioactivation of eptaloprost in animals and man. Hildebrand, M, 1993) | 2.07 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cica-, eptalo- and iloprost are chemically and metabolically stabilized derivatives of prostacyclin which maintain the pharmacodynamic profile of the endogenous precursor." | ( Inter-species extrapolation of pharmacokinetic data of three prostacyclin-mimetics. Hildebrand, M, 1994) | 0.29 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (40.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||